RAD51C
About
Location: 17q22
Mappings
Biomarkers
RAD51C is involved in the following curated biomarkers.
| Name | Biomarker type | Propositions | Statements |
|---|---|---|---|
| RAD51C pathogenic variants | Germline Variant | 2 | 2 |
| RAD51C oncogenic variants | Somatic Variant | 2 | 2 |
Therapeutic response
Precision oncology relationships for therapeutic response involving this gene.
| Organization(s) | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| FDA (1) | RAD51C pathogenic variants | Prostate Adenocarcinoma | Olaparib | |
| FDA (1) | RAD51C pathogenic variants | Prostate Adenocarcinoma | Enzalutamide, Talazoparib | |
| FDA (1) | RAD51C oncogenic variants | Prostate Adenocarcinoma | Olaparib | |
| FDA (1) | RAD51C oncogenic variants | Prostate Adenocarcinoma | Enzalutamide, Talazoparib |